<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27206718</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>07</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>01</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-4159</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>139 Suppl 1</Volume>
            <Issue>Suppl Suppl 1</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurochemistry</Title>
          <ISOAbbreviation>J Neurochem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Diversity matters - heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson's Disease.</ArticleTitle>
        <Pagination>
          <StartPage>8</StartPage>
          <EndPage>26</EndPage>
          <MedlinePgn>8-26</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jnc.13670</ELocationID>
        <Abstract>
          <AbstractText>Dopaminergic neurons in the ventral mesencephalon (the ventral mesencephalic dopaminergic complex) are known for their role in a multitude of behaviors, including cognition, reward, addiction and voluntary movement. Dysfunctions of these neurons are the underlying cause of various neuropsychiatric disorders, such as depression, addiction and schizophrenia. In addition, Parkinson's disease (PD), which is the second most common degenerative disease in developed countries, is characterized by the degeneration of dopaminergic neurons, leading to the core motor symptoms of the disease. However, only a subset of dopaminergic neurons in the ventral mesencephalon is highly vulnerable to the disease process. Indeed, research over several decades revealed that the neurons in the ventral mesencephalic dopaminergic complex do not form a homogeneous group with respect to anatomy, physiology, function, molecular identity or vulnerability/dysfunction in different diseases. Here, we review how the concept of dopaminergic neuron diversity, assisted by the advent and application of new technologies, evolved and was refined over time and how it shaped our understanding of PD pathogenesis. Understanding this diversity of neurons in the ventral mesencephalic dopaminergic complex at all levels is imperative for the development of new and more selective drugs for both PD and various other neuropsychiatric diseases. Several decades of research revealed that the neurons in the ventral mesencephalic dopaminergic complex do not form a homogeneous group in respect to anatomy, physiology, function, molecular identity or vulnerability/dysfunction in diseases like Parkinson's disease (PD). Here, we review how this concept evolved and was refined over time and how it shaped our understanding of the pathogenesis of PD. Source of the midbrain image: www.wikimd.org/wiki/index.php/The_Midbrain_or_Mesencephalon; downloaded 28.01.2016. See also Figures and of the paper. This article is part of a special issue on Parkinson disease.</AbstractText>
          <CopyrightInformation>© 2016 The Authors. Journal of Neurochemistry published by John Wiley &amp; Sons Ltd on behalf of International Society for Neurochemistry.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vogt Weisenhorn</LastName>
            <ForeName>Daniela Maria</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Developmental Genetics, Neuherberg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Technische Universität München-Weihenstephan, Lehrstuhl für Entwicklungsgenetik, c/o Helmholtz Zentrum München, Neuherberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giesert</LastName>
            <ForeName>Florian</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Developmental Genetics, Neuherberg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Technische Universität München-Weihenstephan, Lehrstuhl für Entwicklungsgenetik, c/o Helmholtz Zentrum München, Neuherberg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wurst</LastName>
            <ForeName>Wolfgang</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Developmental Genetics, Neuherberg, Germany. wurst@helmholtz-muenchen.de.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Technische Universität München-Weihenstephan, Lehrstuhl für Entwicklungsgenetik, c/o Helmholtz Zentrum München, Neuherberg, Germany. wurst@helmholtz-muenchen.de.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Standort München, München, Germany. wurst@helmholtz-muenchen.de.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Munich Cluster for Systems Neurology (SyNergy), Adolf-Butenandt-Institut, Ludwig-Maximilians-Universität München, München, Germany. wurst@helmholtz-muenchen.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>06</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neurochem</MedlineTA>
        <NlmUniqueID>2985190R</NlmUniqueID>
        <ISSNLinking>0022-3042</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008636" MajorTopicYN="N">Mesencephalon</DescriptorName>
          <QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName>
          <QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Parkinson's disease</Keyword>
        <Keyword MajorTopicYN="Y">conditional mutagenesis</Keyword>
        <Keyword MajorTopicYN="Y">history</Keyword>
        <Keyword MajorTopicYN="Y">neuroanatomy</Keyword>
        <Keyword MajorTopicYN="Y">single-cell analysis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27206718</ArticleId>
        <ArticleId IdType="pmc">PMC5096020</ArticleId>
        <ArticleId IdType="doi">10.1111/jnc.13670</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Afonso‐Oramas D., Cruz‐Muros I., Alvarez de la Rosa D.
et al (2009) Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. Neurobiol. Dis.
36, 494–508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19766189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Amemori K. and Graybiel A. M. (2012) Localized microstimulation of primate pregenual cingulate cortex induces negative decision‐making. Nat. Neurosci.
15, 776–785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3369110</ArticleId>
            <ArticleId IdType="pubmed">22484571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Anden N. E., Carlsson A., Dahlstroem A., Fuxe K., Hillarp N. A. and Larsson K. (1964) Demonstration and mapping out of nigro‐neostriatal dopamine neurons. Life Sci.
3, 523–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14187491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Anderegg A., Poulin J.‐F. and Awatramani R. (2015) Molecular heterogeneity of midbrain dopaminergic neurons – Moving toward single cell resolution. FEBS Lett.
589, 3714–3726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4679573</ArticleId>
            <ArticleId IdType="pubmed">26505674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Arenas E., Denham M. and Villaescusa J. C. (2015) How to make a midbrain dopaminergic neuron. Development
142, 1918–1936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26015536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bader V., Ran Zhu X., Lubbert H. and Stichel C. C. (2005) Expression of DJ‐1 in the adult mouse CNS. Brain Res.
1041, 102–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15804505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baker H., Joh T. H. and Reis D. J. (1980) Genetic control of number of midbrain dopaminergic neurons in inbred strains of mice: relationship to size and neuronal density of the striatum. Proc. Natl Acad. Sci. USA
77, 4369–4373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC349836</ArticleId>
            <ArticleId IdType="pubmed">6107905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barker D. J., Root D. H., Zhang S. and Morales M. (2016) Multiplexed neurochemical signaling by neurons of the ventral tegmental area. J. Chem. Neuroanat. 2016; 73, 33–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4818729</ArticleId>
            <ArticleId IdType="pubmed">26763116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Beier Kevin T., Steinberg Elizabeth E., DeLoach Katherine E.
et al (2015) Circuit architecture of VTA dopamine neurons revealed by systematic input‐output mapping. Cell
162, 622–634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4522312</ArticleId>
            <ArticleId IdType="pubmed">26232228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bentivoglio M. and Morelli M. (2005) Chapter I The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain, in Handbook of Chemical Neuroanatomy (Dunnett M. B. A. B. S. B. and Hökfelt T., eds), Vol. 21, pp. 1–107. Elsevier Science, USA.</Citation>
        </Reference>
        <Reference>
          <Citation>
Bereczki D. (2010) The description of all four cardinal signs of Parkinson's disease in a Hungarian medical text published in 1690. Parkinsonism Relat. Disord.
16, 290–293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19948422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bertler Å., Carlsson A. and Rosengren E. (1958) A method for the fluorimetric determination of adrenaline and noradrenaline in tissues. 1. Acta Physiol. Scand.
44, 273–292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13617023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Björklund A. and Dunnett S. B. (2007) Dopamine neuron systems in the brain: an update. Trends Neurosci.
30, 194–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17408759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Blackinton J. G., Anvret A., Beilina A., Olson L., Cookson M. R. and Galter D. (2007) Expression of PINK1 mRNA in human and rodent brain and in Parkinson's disease. Brain Res.
1184, 10–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17950257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Blocq P. and Marinesco G. (1892) Sur un cas de tremblement parinsonien hémiplégique symptomatique d'une tumeur du pédoncule cèrèbral. C R Soc. Biol.
5, 105–111.</Citation>
        </Reference>
        <Reference>
          <Citation>
Bodea G. O. and Blaess S. (2015) Establishing diversity in the dopaminergic system. FEBS Lett.
589, 3773–3785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26431946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bolam J. P. and Smith Y. (1990) The GABA and substance P input to dopaminergic neurones in the substantia nigra of the rat. Brain Res.
529, 57–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1704287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Braak H., Tredici K. D., Rüb U., de Vos R. A. I., Jansen Steur E. N. H. and Braak E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging
24, 197–211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12498954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Branda C. S. and Dymecki S. M. (2004) Talking about a revolution: the impact of site‐specific recombinases on genetic analyses in mice. Dev. Cell
6, 7–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14723844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brichta L. and Greengard P. (2014) Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update. Front. Neuroanat., 8, 152 (eCollection).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4266033</ArticleId>
            <ArticleId IdType="pubmed">25565977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brimblecombe K. R. and Cragg S. J. (2015) Substance P weights striatal dopamine transmission differently within the striosome‐matrix axis. J. Neurosci.
35, 9017–9023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4469733</ArticleId>
            <ArticleId IdType="pubmed">26085627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brissaud E. (1893) Nature et pathogénie de la maladie de Parkinson, Lecon sur les maladies nerveuses (Salpêtriere, 1893–1894), Vol. 1, pp. 488–501. Masson, Paris.</Citation>
        </Reference>
        <Reference>
          <Citation>
der van Brug M. P., Singleton A., Gasser T. and Lewis P. A. (2015) Parkinson's disease: from human genetics to clinical trials. Sci. Transl. Med., 7, 205 ps220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5995146</ArticleId>
            <ArticleId IdType="pubmed">26378242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burdach K. F. (1822) Vom Baue und Leben des Gehirns. KF Burdach, Leipzig.</Citation>
        </Reference>
        <Reference>
          <Citation>
Cai H., Liu G., Sun L. and Ding J. (2014a) Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson's disease. Transl. Neurodegener.
3, 27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4334846</ArticleId>
            <ArticleId IdType="pubmed">25705376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cai X., Evrony G. D., Lehmann H. S., Elhosary P. C., Mehta B. K., Poduri A. and Walsh C. A. (2014b) Single‐cell, genome‐wide sequencing identifies clonal somatic copy‐number variation in the human brain. Cell Rep.
8, 1280–1289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4272008</ArticleId>
            <ArticleId IdType="pubmed">25159146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Callaway E. M. and Luo L. (2015) Monosynaptic circuit tracing with glycoprotein‐deleted rabies viruses. J. Neurosci.
35, 8979–8985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4469731</ArticleId>
            <ArticleId IdType="pubmed">26085623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carlsson A. (1959) The occurence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev.
11, 490–493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13667431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carlsson A., Lindqvist M. and Magnusson T. O. R. (1957) 3,4‐dihydroxyphenylalanine and 5‐hydroxytryptophan as reserpine antagonists. Nature
180, 1200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13483658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carlsson A., Lindquist M., Magnusson T. and Waldeck B. (1958) On the presence of 3‐hydroxytyramine in brain. Science
127, 471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13529006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carlsson A., Falck B. and Hillarp N. A. (1962) Cellular localization of brain monoamines. Acta Physiologica Scandinavica Supplement
56, 1–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14018711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Charcot J. M. (1892) Oeuvres Complètes, Buereaux du Progrès Médical, Paris.</Citation>
        </Reference>
        <Reference>
          <Citation>
Chen Y., Zheng Y., Kang Y.
et al (2015) Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. Hum. Mol. Genet.
24, 3764–3774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5007610</ArticleId>
            <ArticleId IdType="pubmed">25859012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chuhma N., Tanaka K. F., Hen R. and Rayport S. (2011) Functional connectome of the striatal medium spiny neuron. J. Neurosci.
31, 1183–1192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3074638</ArticleId>
            <ArticleId IdType="pubmed">21273403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chuhma N., Mingote S., Moore H. and Rayport S. (2014) Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling. Neuron
81, 901–912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3933825</ArticleId>
            <ArticleId IdType="pubmed">24559678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chung C. Y., Seo H., Sonntag K. C., Brooks A., Lin L. and Isacson O. (2005) Cell type‐specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet.
14, 1709–1725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2674782</ArticleId>
            <ArticleId IdType="pubmed">15888489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cowan W. M., Gottlieb D. I., Hendrickson A. E., Price J. L. and Woolsey T. A. (1972) The autoradiographic demonstration of axonal connections in the central nervous system. Brain Res.
37, 21–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4110604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crittenden J. R. and Graybiel A. M. (2011) Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front. Neuroanat.
5, 59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3171104</ArticleId>
            <ArticleId IdType="pubmed">21941467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dahlström A. and Fuxe K. (1964) Evidence for the existence of monoamine‐containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiologica Scandinavica Supplement
232, 1–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14229500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Damier P., Hirsch E. C., Agid Y. and Graybiel A. M. (1999a) The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain, 122 (Pt 8), 1421–1436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10430829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Damier P., Hirsch E. C., Agid Y. and Graybiel A. M. (1999b) The substantia nigra of the human brain. II. Patterns of loss of dopamine‐containing neurons in Parkinson's disease. Brain, 122 (Pt 8), 1437–1448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10430830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dawson T. M., Ko H. S. and Dawson V. L. (2010) Genetic animal models of Parkinson's disease. Neuron
66, 646–661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2917798</ArticleId>
            <ArticleId IdType="pubmed">20547124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dehay B., Vila M., Bezard E., Brundin P. and Kordower J. H. (2016) Alpha‐synuclein propagation: new insights from animal models. Mov. Disord.
31, 161–168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26347034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Di Salvio M., Di Giovannantonio L. G., Acampora D., Prosperi R., Omodei D., Prakash N., Wurst W. and Simeone A. (2010a) Otx2 controls neuron subtype identity in ventral tegmental area and antagonizes vulnerability to MPTP. Nat. Neurosci.
13, 1481–1488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21057506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Di Salvio M., Di Giovannantonio L. G., Omodei D., Acampora D. and Simeone A. (2010b) Otx2 expression is restricted to dopaminergic neurons of the ventral tegmental area in the adult brain. Inter. J. Develop. Biol.
54, 939–945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19924631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Double K. L., Reyes S., Werry E. L. and Halliday G. M. (2010) Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions?
Prog. Neurobiol.
92, 316–329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20541584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dueck H., Khaladkar M., Kim T. K.
et al (2015) Deep sequencing reveals cell‐type‐specific patterns of single‐cell transcriptome variation. Genome Biol.
16, 122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4480509</ArticleId>
            <ArticleId IdType="pubmed">26056000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dueck H., Eberwine J. and Kim J. (2016) Variation is function: are single cell differences functionally important?: testing the hypothesis that single cell variation is required for aggregate function. BioEssays
38, 172–180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4738397</ArticleId>
            <ArticleId IdType="pubmed">26625861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Edinger L. (1911) Vorlesungen über den Bau der nervösen Zentralorgane des Menschen und der Tiere: für Ärzte und Studierende, Vol. 1. FCW Vogel, Leipzig.</Citation>
        </Reference>
        <Reference>
          <Citation>
Ehringer H. and Hornykiewitcz O. (1960) Verteilung von noradrenalin und dopamin (3‐Hydroxytyramin) im Gehirn des menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen systems. Klinisch. Wochenschrift
38, 1236–1239.</Citation>
        </Reference>
        <Reference>
          <Citation>
Ekstrand M. I., Nectow A. R., Knight Z. A., Latcha K. N., Pomeranz L. E. and Friedman J. M. (2014) Molecular profiling of neurons based on connectivity. Cell
157, 1230–1242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4854627</ArticleId>
            <ArticleId IdType="pubmed">24855954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
El Mestikawy S., Wallen‐Mackenzie A., Fortin G. M., Descarries L. and Trudeau L. E. (2011) From glutamate co‐release to vesicular synergy: vesicular glutamate transporters. Nat. Rev. Neurosci.
12, 204–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21415847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Erwin J. A., Marchetto M. C. and Gage F. H. (2014) Mobile DNA elements in the generation of diversity and complexity in the brain. Nat. Rev. Neurosci.
15, 497–506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4443810</ArticleId>
            <ArticleId IdType="pubmed">25005482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Falck B., Hillarp N.‐Å., Thieme G. and Torp A. (1962) Flourescence of catecholamines and related compounds condensed with formaldehyde. J. Histochem. Cytochem.
10, 348–354.</Citation>
        </Reference>
        <Reference>
          <Citation>
Fallon J. H. and Loughlin S. E. (1995) Substantia nigra, in The Rat Nervous System, (Paxinos G., ed.), pp. 215–236. Academic Press, San Diego.</Citation>
        </Reference>
        <Reference>
          <Citation>
Fallon J. H. and Moore R. Y. (1978a) Catecholamine innervation of the basal forebrain. III. Olfactory bulb, anterior olfactory nuclei, olfactory tubercle and piriform cortex. J. Comp. Neurol.
180, 533–544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">307009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fallon J. H. and Moore R. Y. (1978b) Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol.
180, 545–580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">659674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fallon J. H., Koziell D. A. and Moore R. Y. (1978) Catecholamine innervation of the basal forebrain. II. Amygdala, suprarhinal cortex and entorhinal cortex. J. Comp. Neurol.
180, 509–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">659673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fearnley J. M. and Lees A. J. (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain
114(Pt 5), 2283–2301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1933245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Feng Y., Jankovic J. and Wu Y. C. (2015) Epigenetic mechanisms in Parkinson's disease. J. Neurol. Sci.
349, 3–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25553963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fink R. P. and Heimer L. (1967) Two methods for selective silver impregnation of degenerating axons and their synaptic endings in the central nervous system. Brain Res.
4, 369–374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4166480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Forel A. (1877) Untersuchungen über die Haubenregion und ihre oberen Verknüpfungen im Gehirne des Menschen und einiger Säugetiere. Archive für Psychiatrie, 7, 393–495.</Citation>
        </Reference>
        <Reference>
          <Citation>
Forel A. (1907) Gesammelte hirnanatomische Abhandlungen mit einem Aufsatz zur Aufgabe der Neurobiologie. Reinhardt, München.</Citation>
        </Reference>
        <Reference>
          <Citation>
Friedman A., Homma D., Gibb Leif G., Amemori K.‐I., Rubin Samuel J., Hood Adam S., Riad Michael H. and Graybiel Ann M. (2015) A corticostriatal path targeting striosomes controls decision‐making under conflict. Cell
161, 1320–1333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4477966</ArticleId>
            <ArticleId IdType="pubmed">26027737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fu Y., Yuan Y., Halliday G., Rusznak Z., Watson C. and Paxinos G. (2012) A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain Struct. Funct.
217, 591–612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21935672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fuzik J., Zeisel A., Mate Z., Calvigioni D., Yanagawa Y., Szabo G., Linnarsson S. and Harkany T. (2015) Integration of electrophysiological recordings with single‐cell RNA‐seq data identifies neuronal subtypes. Nat. Biotech.
34, 175–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4745137</ArticleId>
            <ArticleId IdType="pubmed">26689544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Geisler S. and Zahm D. S. (2005) Afferents of the ventral tegmental area in the rat‐anatomical substratum for integrative functions. J. Comp. Neurol.
490, 270–294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16082674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gerfen C. R. (2004) Basal ganglia, in The Rat Nervous System, (Paxinos G., ed.), pp. 455–508. Elsevier, Amsterdam.</Citation>
        </Reference>
        <Reference>
          <Citation>
German D. C. and Manaye K. F. (1993) Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three‐dimensional reconstruction in the rat. J. Comp. Neurol.
331, 297–309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8514911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Giesert F., Hofmann A., Burger A.
et al (2013) Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice. PLoS ONE
8, e63778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3651128</ArticleId>
            <ArticleId IdType="pubmed">23675505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goetz C. G. (1986) Charcot on Parkinson's disease. Mov. Disord.
1, 27–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3332804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gray H. (1918) Anatomy of the Human Body. Lea &amp; Febiger, Philadelphia; Bartleby.com, 2000. www.bartleby.com/107/.</Citation>
        </Reference>
        <Reference>
          <Citation>
Greene J. G., Dingledine R. and Greenamyre J. T. (2005) Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol. Dis.
18, 19–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15649693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Greffard S., Verny M., Bonnet A. M., Beinis J. Y., Gallinari C., Meaume S., Piette F., Hauw J. J. and Duyckaerts C. (2006) Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body‐associated neuronal loss in the substantia nigra. Arch. Neurol.
63, 584–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16606773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grimm J., Mueller A., Hefti F. and Rosenthal A. (2004) Molecular basis for catecholaminergic neuron diversity. Proc. Natl Acad. Sci. USA
101, 13891–13896.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC518849</ArticleId>
            <ArticleId IdType="pubmed">15353588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gubellini P. and Kachidian P. (2015) Animal models of Parkinson's disease: an updated overview. Rev. Neurol. (Paris)
171, 750–761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26343921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guo J. U., Su Y., Shin J. H.
et al (2014) Distribution, recognition and regulation of non‐CpG methylation in the adult mammalian brain. Nat. Neurosci.
17, 215–222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3970219</ArticleId>
            <ArticleId IdType="pubmed">24362762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Haber S. N. (2014) The place of dopamine in the cortico‐basal ganglia circuit. Neuroscience
282, 248–257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5484174</ArticleId>
            <ArticleId IdType="pubmed">25445194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Haber S. N., Fudge J. L. and McFarland N. R. (2000) Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J. Neurosci.
20, 2369–2382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6772499</ArticleId>
            <ArticleId IdType="pubmed">10704511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hardman C. D., Henderson J. M., Finkelstein D. I., Horne M. K., Paxinos G. and Halliday G. M. (2002) Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J. Comp. Neurol.
445, 238–255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11920704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hassler R. (1938) Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol.
48, 387–455.</Citation>
        </Reference>
        <Reference>
          <Citation>
Hatami A. and Chesselet M. F. (2015) Transgenic rodent models to study alpha‐synuclein pathogenesis, with a focus on cognitive deficits. Curr. Top. Behav. Neurosci.
22, 303–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25218491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hattori T. (1993) Conceptual history of the nigrostriatal dopamine system. Neurosci. Res.
16, 239–262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8394552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hökfelt T., Mårtensson R., Björklund A., Kleinau A. and Goldstein M. (1984) Distributional maps of tyrosine‐hydroxylase‐immunoreactive neurons in the rat brain, in Handbook of Chemical Neuroanatomy (Björklund A. and Hökfelt T., eds), Vol. 2: Classical Transmitters in the CNS, Part I, pp. 277–379. Elsevier, Amsterdam.</Citation>
        </Reference>
        <Reference>
          <Citation>
Holmes G. M. (1901) The nervous system of the dog without a forebrain. J. Physiol.
27, 1–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1540548</ArticleId>
            <ArticleId IdType="pubmed">16992595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hornykiewitcz O. (1963) Die topische Lokalisation und das Verhalten von Naradrenalin und dopamin (3‐Hydroxytyramin) in der Substantia nigra des normalen und des parkinsonkranken Menschen. Wien. Klin. Wochenschr.
75, 309–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13954967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hornykiewitcz O. (1992) From dopamine to Parkinson's disease: a personal research record, in The Neurosciences: Paths of Discovery II, (Adelman S. A. ed.). Birkhäuser, Basel.</Citation>
        </Reference>
        <Reference>
          <Citation>
Huber G. C., Crosby E. C., Woodburne R. T., Gillilan L. A., Brown J. O. and Tamthai B. (1943) The mammalian midbrain and isthmus regions. J. Comp. Neurol.
78, 129–530.</Citation>
        </Reference>
        <Reference>
          <Citation>
Joel D. and Weiner I. (2000) The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience
96, 451–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10717427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kaushal D., Contos J. J., Treuner K.
et al (2003) Alteration of gene expression by chromosome loss in the postnatal mouse brain. J. Neurosci.
23, 5599–5606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6741244</ArticleId>
            <ArticleId IdType="pubmed">12843262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim J.‐I., Ganesan S., Luo S. X., Wu Y.‐W., Park E., Huang E. J., Chen L. and Ding J. B. (2015) Aldehyde dehydrogenase 1a1 mediates a GABA synthesis pathway in midbrain dopaminergic neurons. Science
350, 102–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4725325</ArticleId>
            <ArticleId IdType="pubmed">26430123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kordower J. H., Olanow C. W., Dodiya H. B., Chu Y., Beach T. G., Adler C. H., Halliday G. M. and Bartus R. T. (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain
136, 2419–2431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3722357</ArticleId>
            <ArticleId IdType="pubmed">23884810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Korotkova T. M., Ponomarenko A. A., Brown R. E. and Haas H. L. (2004) Functional diversity of ventral midbrain dopamine and GABAergic neurons. Mol. Neurobiol.
29, 243–259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15181237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lammel S., Hetzel A., Hackel O., Jones I., Liss B. and Roeper J. (2008) Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron
57, 760–773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18341995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lammel S., Ion D. I., Roeper J. and Malenka R. C. (2011) Projection‐specific modulation of dopamine neuron synapses by aversive and rewarding stimuli. Neuron
70, 855–862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3112473</ArticleId>
            <ArticleId IdType="pubmed">21658580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lammel S., Lim B. K., Ran C., Huang K. W., Betley M. J., Tye K. M., Deisseroth K. and Malenka R. C. (2012) Input‐specific control of reward and aversion in the ventral tegmental area. Nature
491, 212–217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3493743</ArticleId>
            <ArticleId IdType="pubmed">23064228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
LaVail J. H. and LaVail M. M. (1972) Retrograde axonal transport in the central nervous system. Science
176, 1416–1417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5033648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lees A. J., Tolosa E. and Olanow C. W. (2015) Four pioneers of L‐dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov. Disord.
30, 19–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25488030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
L'Episcopo F., Serapide M. F., Tirolo C., Testa N., Caniglia S., Morale M. C., Pluchino S. and Marchetti B. (2011a) A Wnt1 regulated Frizzled‐1/beta‐Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron‐astrocyte crosstalk: therapeutical relevance for neuron survival and neuroprotection. Mol. Neurodegener.
6, 49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3162575</ArticleId>
            <ArticleId IdType="pubmed">21752258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
L'Episcopo F., Tirolo C., Testa N.
et al (2011b) Reactive astrocytes and Wnt/β‐catenin signaling link nigrostriatal injury to repair in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine model of Parkinson's disease. Neurobiol. Dis.
41, 508–527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3558878</ArticleId>
            <ArticleId IdType="pubmed">21056667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
L'Episcopo F., Tirolo C., Caniglia S., Testa N., Morale M. C., Serapide M. F., Pluchino S. and Marchetti B. (2014) Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. J. Mol. Cell Biol.
6, 13–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4061726</ArticleId>
            <ArticleId IdType="pubmed">24431301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lerner T. N., Shilyansky C., Davidson T. J.
et al (2015) Intact‐brain analyses reveal distinct information carried by SNc dopamine subcircuits. Cell
162, 635–647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4790813</ArticleId>
            <ArticleId IdType="pubmed">26232229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lerner Talia N., Ye L. and Deisseroth K. (2016) Communication in neural circuits: tools, opportunities, and challenges. Cell
164, 1136–1150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5725393</ArticleId>
            <ArticleId IdType="pubmed">26967281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lewis D. A., Sesack S. R., Levey A. I. and Rosenberg D. R. (1998) Dopamine axons in primate prefrontal cortex: specificity of distribution, synaptic targets, and development. Adv. Pharmacol. (San Diego, Calif.), 42, 703–706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9327996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lewy F. H. (1912) Paralysis agitans. I. Pathologische Anatomie, in Handbuch der Neurologie, (Lewandowsky M. ed.), Vol. III. 920–933. Springer, Berlin.</Citation>
        </Reference>
        <Reference>
          <Citation>
Li J., Duarte T., Kocabas A., Works M., McConnell S. K. and Hynes M. A. (2014) Evidence for topographic guidance of dopaminergic axons by differential Netrin‐1 expression in the striatum. Mol. Cell Neurosci.
61, 85–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24867253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liss B., Haeckel O., Wildmann J., Miki T., Seino S. and Roeper J. (2005) K‐ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci.
8, 1742–1751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16299504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu G., Yu J., Ding J.
et al (2014) Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. J. Clin. Invest.
124, 3032–3046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4071380</ArticleId>
            <ArticleId IdType="pubmed">24865427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lodato M. A., Woodworth M. B., Lee S.
et al (2015) Somatic mutation in single human neurons tracks developmental and transcriptional history. Science
350, 94–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4664477</ArticleId>
            <ArticleId IdType="pubmed">26430121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lovatt D., Ruble B. K., Lee J.
et al (2014) Transcriptome In Vivo Analysis (TIVA) of spatially defined single cells in intact live mouse and human brain tissue. Nat. Methods
11, 190–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3964595</ArticleId>
            <ArticleId IdType="pubmed">24412976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Luys J. (1865) Recherches sur le système cérébro‐spinal, sa structure, ses fonctions et ses maladies, Baillière et Fils, Paris.</Citation>
        </Reference>
        <Reference>
          <Citation>
Ma T. P. (1989) Identification of the substantia nigra pars lateralis in the macaque using cytochrome oxidase and fiber stains. Brain Res.
480, 305–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2469515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ma S. Y., Röyttä M., Rinne J. O., Collan Y. and Rinne U. K. (1997) Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J. Neurol. Sci.
151, 83–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9335015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Macosko Evan Z., Basu A., Satija R.
et al (2015) Highly parallel genome‐wide expression profiling of individual cells using nanoliter droplets. Cell
161, 1202–1214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4481139</ArticleId>
            <ArticleId IdType="pubmed">26000488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Manyam B. V. (1990) Paralysis agitans and levodopa in “Ayurveda”: ancient Indian medical treatise. Mov. Disord.
5, 47–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2404203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Matsuda W., Furuta T., Nakamura K. C., Hioki H., Fujiyama F., Arai R. and Kaneko T. (2009) Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci.
29, 444–453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6664950</ArticleId>
            <ArticleId IdType="pubmed">19144844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Matsumoto M. and Hikosaka O. (2009) Two types of dopamine neuron distinctly convey positive and negative motivational signals. Nature
459, 837–841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2739096</ArticleId>
            <ArticleId IdType="pubmed">19448610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McConnell M. J., Lindberg M. R., Brennand K. J.
et al (2013) Mosaic copy number variation in human neurons. Science
342, 632–637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3975283</ArticleId>
            <ArticleId IdType="pubmed">24179226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Menegas W., Bergan J. F., Ogawa S. K., Isogai Y., Umadevi Venkataraju K., Osten P., Uchida N. and Watabe‐Uchida M. (2015) Dopamine neurons projecting to the posterior striatum form an anatomically distinct subclass. eLife, 4, e10032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4598831</ArticleId>
            <ArticleId IdType="pubmed">26322384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Meynert T. (1884) Psychiatrie: Klinik der Erkrankungen des Vorderhirns begründet auf dessen Bau, Leistungen und Ernährung : 1. Hälfte. (Bogen 1‐18). W. Braumüller, Wien.</Citation>
        </Reference>
        <Reference>
          <Citation>
Mingazzini G. (1889) Sur la fine structure de la substantia nigra Soemmeringi. Archives Italliennes de Biologie
12, 93–98.</Citation>
        </Reference>
        <Reference>
          <Citation>
Mingote S., Chuhma N., Kusnoor S. V. and Field B. (2015) Functional connectome analysis of dopamine neuron glutamatergic connections in forebrain regions. J. Neurosci.
35, 16259–16271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4682788</ArticleId>
            <ArticleId IdType="pubmed">26658874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Monakow C. (1895) Experimentelle und pathologisch‐anatomische Untersuchungen über die Haubenregion, den Sehhügel und die Regio subthalamica, nebst Beiträgen zur Kenntniss früh erworbener Gross‐ und Kleinhirndefekte. Archiv f. Psychiatrie.
27, 386–478.</Citation>
        </Reference>
        <Reference>
          <Citation>
Moore R. Y. (1970) Brain Lesions and Amine Metabolism, in International Review of Neurobiology, (Carl C. P. and John R. S. eds.), Vol. 13, pp. 67–91. Elsevier, Amsterdam.</Citation>
        </Reference>
        <Reference>
          <Citation>
Moore R. Y. and Heller A. (1967) Subcortical systems participating in the control of caudate nucleus dopamine content, in Progress in Neurogenetics, (Barbeau A. and Brunette J. R., eds.), pp. 276–282. Excerpta Medica Foundation, Amsterdam.</Citation>
        </Reference>
        <Reference>
          <Citation>
Muthane U., Ramsay K. A., Jiang H., Jackson‐Lewis V., Donaldson D., Fernando S., Ferreira M. and Przedborski S. (1994) Differences in nigral neuron number and sensitivity to 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in C57/bl and CD‐1 mice. Exp. Neurol.
126, 195–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7925820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nandhagopal R., Kuramoto L., Schulzer M.
et al (2011) Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain
134, 3290–3298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22075521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nauta W. J. H. (1993) Some early travails of tracing axonal pathways in the brain. J. Neurosci.
13, 1337–1345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6576740</ArticleId>
            <ArticleId IdType="pubmed">8463822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nauta W. J. H. and Gygax P. A. (1954) Silver impregnation of degenerating axons in the central nervous system: a modified technique. Stain Technol.
29, 91–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13146411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nectow A. R., Ekstrand M. I. and Friedman J. M. (2015) Molecular characterization of neuronal cell types based on patterns of projection with Retro‐TRAP. Nat. Protoc.
10, 1319–1327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26247298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nelson E. L., Liang C. L., Sinton C. M. and German D. C. (1996) Midbrain dopaminergic neurons in the mouse: computer‐assisted mapping. J. Comp. Neurol.
369, 361–371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8743418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Niu Y., Shen B., Cui Y.
et al (2014) Generation of gene‐modified cynomolgus monkey via Cas9/RNA‐mediated gene targeting in one‐cell embryos. Cell
156, 836–843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24486104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Oades R. D. and Halliday G. M. (1987) Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Res. Rev.
12, 117–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3107759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Osborne P. B., Halliday G. M., Cooper H. M. and Keast J. R. (2005) Localization of immunoreactivity for deleted in colorectal cancer (DCC), the receptor for the guidance factor netrin‐1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience
131, 671–681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15730872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pacelli C., Giguere N., Bourque M. J., Levesque M., Slack R. S. and Trudeau L. E. (2015) Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons. Curr. Biol.
25, 2349–2360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26320949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pagonabarraga J., Kulisevsky J., Strafella A. P. and Krack P. (2015) Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol.
14, 518–531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25895932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pan W. X., Mao T. and Dudman J. T. (2010) Inputs to the dorsal striatum of the mouse conserve the parallel circuit architecture of the forebrain. Front. Neuroanat.
4, 147 (eCollection).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3014656</ArticleId>
            <ArticleId IdType="pubmed">21212837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Panman L., Papathanou M., Laguna A.
et al (2014) Sox6 and Otx2 control the specification of substantia nigra and ventral tegmental area dopamine neurons. Cell Rep.
8, 1018–1025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25127144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Parent M. and Parent A. (2006) Relationship between axonal collateralization and neuronal degeneration in basal ganglia. J. Neural. Transm. Supplementum, 70, 85–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17017513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Parent M. and Parent A. (2010) Substantia nigra and Parkinson's disease: a brief history of their long and Intimate relationship. Can. J. Neurol. Sci.
37, 313–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20481265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Páriz F. P. (1690) Pax corporis, az az az emberi testnek belsT nyavalyáinak okairól, fészkeirTl ‘s azoknak orvoslásának módgyáról való tracta. (“Pax corporis, i.e., a teaching of the causes, sources and the methods of treatment of the internal diseases of the human body”). Némethi Mihály, Kolozsvár, Hungary.</Citation>
        </Reference>
        <Reference>
          <Citation>
Parkkinen L., O'Sullivan S. S., Collins C., Petrie A., Holton J. L., Revesz T. and Lees A. J. (2011) Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease. J. Parkinson's Dis.
1, 277–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4196643</ArticleId>
            <ArticleId IdType="pubmed">23939308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Petersen K., Olesen O. F. and Mikkelsen J. D. (1999) Developmental expression of alpha‐synuclein in rat hippocampus and cerebral cortex. Neuroscience
91, 651–659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10366022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pham T. T., Giesert F., Rothig A.
et al (2010) DJ‐1‐deficient mice show less TH‐positive neurons in the ventral tegmental area and exhibit non‐motoric behavioural impairments. Genes Brain Behav.
9, 305–317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20039949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pickrell A. M., Pinto M. and Moraes C. T. (2013) Mouse models of Parkinson's disease associated with mitochondrial dysfunction. Mol. Cell Neurosci.
55, 87–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3997253</ArticleId>
            <ArticleId IdType="pubmed">22954895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pirritano D., Plastino M., Bosco D., Gallelli L., Siniscalchi A. and De Sarro G. (2014) Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review. BioMed Res. Inter.
2014, 728038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4119624</ArticleId>
            <ArticleId IdType="pubmed">25114917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Poulin J.‐F., Zou J., Drouin‐Ouellet J., Kim K. Y., Cicchetti F. and Awatramani R. B. (2014) Defining midbrain dopaminergic neuron diversity by single‐cell gene expression profiling. Cell Rep., 9, 930–943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4251558</ArticleId>
            <ArticleId IdType="pubmed">25437550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prakash N., Brodski C., Naserke T.
et al (2006) A Wnt1‐regulated genetic network controls the identity and fate of midbrain‐dopaminergic progenitors in vivo. Development
133, 89–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16339193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prestoz L., Jaber M. and Gaillard A. (2012) Dopaminergic axon guidance: which makes what?
Front. Cell. Neurosci.
6, 32 (eCollection).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3408579</ArticleId>
            <ArticleId IdType="pubmed">22866028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pupe S. and Wallen‐Mackenzie A. (2015) Cre‐driven optogenetics in the heterogeneous genetic panorama of the VTA. Trends Neurosci.
38, 375–386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25962754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rajewsky K., Gu H., Kuhn R., Betz U. A., Muller W., Roes J. and Schwenk F. (1996) Conditional gene targeting. J. Clin. Invest.
98, 600–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC507466</ArticleId>
            <ArticleId IdType="pubmed">8698848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ramon Y. and Cajal S. (1899. ‐1904) Textura del sistema nervioso del hombre y de los vertebrados, Moya, Madrid.</Citation>
        </Reference>
        <Reference>
          <Citation>
Reyes S., Fu Y., Double K., Thompson L., Kirik D., Paxinos G. and Halliday G. M. (2012) GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. J. Comp. Neurol.
520, 2591–2607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22252428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Reyes S., Cottam V., Kirik D., Double K. L. and Halliday G. M. (2013a) Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov. Disord.
28, 1351–1359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23674405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Reyes S., Fu Y., Double K. L.
et al (2013b) Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. Neurobiol. Aging
34, 873–886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22926168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Roeper J. (2013) Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci.
36, 336–342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23582338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Root D. H., Mejias‐Aponte C. A., Zhang S., Wang H. L., Hoffman A. F., Lupica C. R. and Morales M. (2014) Single rodent mesohabenular axons release glutamate and GABA. Nat. Neurosci.
17, 1543–1551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4843828</ArticleId>
            <ArticleId IdType="pubmed">25242304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosen B., Schick J. and Wurst W. (2015) Beyond knockouts: the International Knockout Mouse Consortium delivers modular and evolving tools for investigating mammalian genes. Mamm. Genome
26, 456–466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26340938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sano T. (1910) Betrag zur vergleichenden Anatomie der substantia nigra, des Corpus Luysii und der Zona incerta. Mschr. Psychiat. Neurol.
27 und 28.</Citation>
        </Reference>
        <Reference>
          <Citation>
Schwarz L. A., Miyamichi K., Gao X. J.
et al (2015) Viral‐genetic tracing of the input‐output organization of a central noradrenaline circuit. Nature
524, 88–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4587569</ArticleId>
            <ArticleId IdType="pubmed">26131933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sider D. and McVaugh M. (1979) Galen on tremor, palpitation, spasm, and rigor. Trans. Stud. Coll. Physicians Phila.
1, 183–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">395733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Simon H. H., Saueressig H., Wurst W., Goulding M. D. and O'Leary D. D. (2001) Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J. Neurosci.
21, 3126–3134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6762576</ArticleId>
            <ArticleId IdType="pubmed">11312297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smith G. A., Isacson O. and Dunnett S. B. (2012) The search for genetic mouse models of prodromal Parkinson's disease. Exp. Neurol.
237, 267–273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22819262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Soemmering S. T. V. (1791) Vom Baue des menschlichen Körpers: Hirnlehre und Nervenlehre. Vol. 5. Varrentrap &amp; Werner, Frankfurt, Germany.</Citation>
        </Reference>
        <Reference>
          <Citation>
Somogyi P., Bolam J. P., Totterdell S. and Smith A. D. (1981) Monosynaptic input from the nucleus accumbens–ventral striatum region to retrogradely labelled nigrostriatal neurones. Brain Res.
217, 245–263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7248789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stamatakis A. M., Jennings J. H., Ung R. L.
et al (2013) A unique population of ventral tegmental area neurons inhibits the lateral habenula to promote reward. Neuron
80, 1039–1053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3873746</ArticleId>
            <ArticleId IdType="pubmed">24267654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stichel C. C., Augustin M., Kuhn K., Zhu X. R., Engels P., Ullmer C. and Lubbert H. (2000) Parkin expression in the adult mouse brain. Eur. J. Neurosci.
12, 4181–4194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11122330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stuber G. D., Hnasko T. S., Britt J. P., Edwards R. H. and Bonci A. (2010) Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate. J. Neurosci.
30, 8229–8233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2918390</ArticleId>
            <ArticleId IdType="pubmed">20554874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sulzer D. (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci.
30, 244–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17418429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tang F., Barbacioru C., Wang Y.
et al (2009) mRNA‐Seq whole‐transcriptome analysis of a single cell. Nat. Methods
6, 377–382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19349980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tecuapetla F., Patel J. C., Xenias H.
et al (2010) Glutamatergic signaling by mesolimbic dopamine neurons in the nucleus accumbens. J. Neurosci.
30, 7105–7110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3842465</ArticleId>
            <ArticleId IdType="pubmed">20484653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Trétiakoff C. (1919) Contribution à l'étude de l'anatomiepathologique du locus niger de Soemmering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. Jouve, Paris.</Citation>
        </Reference>
        <Reference>
          <Citation>
Tritsch N. X., Ding J. B. and Sabatini B. L. (2012) Dopaminergic neurons inhibit striatal output through non‐canonical release of GABA. Nature
490, 262–266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3944587</ArticleId>
            <ArticleId IdType="pubmed">23034651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tritsch N. X., Granger A. J. and Sabatini B. L. (2016) Mechanisms and functions of GABA co‐release. Nat. Rev. Neurosci.
17, 139–145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6980171</ArticleId>
            <ArticleId IdType="pubmed">26865019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Trudeau L. E., Hnasko T. S., Wallen‐Mackenzie A., Morales M., Rayport S. and Sulzer D. (2014) The multilingual nature of dopamine neurons. Prog. Brain Res.
211, 141–164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4565795</ArticleId>
            <ArticleId IdType="pubmed">24968779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tsai C. (1925) The optic tracts and centers of the opossum. Didelphis virginiana. J. Comp. Neurol.
39, 173–216.</Citation>
        </Reference>
        <Reference>
          <Citation>
Tu Z., Yang W., Yan S., Guo X. and Li X. J. (2015) CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases. Mol. Neurodegener.
10, 35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4524001</ArticleId>
            <ArticleId IdType="pubmed">26238861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Usoskin D., Furlan A., Islam S.
et al (2015) Unbiased classification of sensory neuron types by large‐scale single‐cell RNA sequencing. Nat. Neurosci.
18, 145–153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25420068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Veenvliet J. and Smidt M. (2014) Molecular mechanisms of dopaminergic subset specification: fundamental aspects and clinical perspectives. Cell. Mol. Life Sci.
71, 4703–4727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25064061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Verstraeten A., Theuns J. and Van Broeckhoven C. (2015) Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet.
31, 140–149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25703649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vicq d'Azyr F. (1786) Traité d'Anatomie et de Physiologie avec des Plances Colorées. Didot, Paris.</Citation>
        </Reference>
        <Reference>
          <Citation>
Watabe‐Uchida M., Zhu L., Ogawa Sachie K., Vamanrao A. and Uchida N. (2012) Whole‐brain mapping of direct inputs to midbrain dopamine neurons. Neuron
74, 858–873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22681690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wickersham I. R., Finke S., Conzelmann K. K. and Callaway E. M. (2007a) Retrograde neuronal tracing with a deletion‐mutant rabies virus. Nat. Methods
4, 47–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2755236</ArticleId>
            <ArticleId IdType="pubmed">17179932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wickersham I. R., Lyon D. C., Barnard R. J., Mori T., Finke S., Conzelmann K. K., Young J. A. and Callaway E. M. (2007b) Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons. Neuron
53, 639–647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2629495</ArticleId>
            <ArticleId IdType="pubmed">17329205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wurst W. and Prakash N. (2014) Wnt1‐regulated genetic networks in midbrain dopaminergic neuron development. J. Mol.Cell. Biol.
6, 34–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24326514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamaguchi T., Sheen W. and Morales M. (2007) Glutamatergic neurons are present in the rat ventral tegmental area. Eur. J. Neurosci.
25, 106–118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3209508</ArticleId>
            <ArticleId IdType="pubmed">17241272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamaguchi T., Wang H. L., Li X., Ng T. H. and Morales M. (2011) Mesocorticolimbic glutamatergic pathway. J. Neurosci.
31, 8476–8490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6623324</ArticleId>
            <ArticleId IdType="pubmed">21653852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamaguchi T., Qi J., Wang H. L., Zhang S. and Morales M. (2015) Glutamatergic and dopaminergic neurons in the mouse ventral tegmental area. Eur. J. Neurosci.
41, 760–772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4363208</ArticleId>
            <ArticleId IdType="pubmed">25572002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yetnikoff L., Lavezzi H. N., Reichard R. A. and Zahm D. S. (2014) An update on the connections of the ventral mesencephalic dopaminergic complex. Neuroscience, 282c, 23–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4195813</ArticleId>
            <ArticleId IdType="pubmed">24735820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zeisel A., Munoz‐Manchado A. B., Codeluppi S.
et al (2015) Brain structure. Cell types in the mouse cortex and hippocampus revealed by single‐cell RNA‐seq. Science
347, 1138–1142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25700174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang J., Gotz S., Vogt Weisenhorn D. M., Simeone A., Wurst W. and Prakash N. (2015a) A WNT1‐regulated developmental gene cascade prevents dopaminergic neurodegeneration in adult En1(+/‐) mice. Neurobiol. Dis.
82, 32–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26049140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang S., Qi J., Li X., Wang H.‐L., Britt J. P., Hoffman A. F., Bonci A., Lupica C. R. and Morales M. (2015b) Dopaminergic and glutamatergic microdomains in a subset of rodent mesoaccumbens axons. Nat. Neurosci.
18, 386–392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4340758</ArticleId>
            <ArticleId IdType="pubmed">25664911</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
